Myris Therapeutics uses breakthrough advances in Polymer Chemistry to engineer novel next-generation medicines. Our flagship platform of ultra-high DAR antibody drug conjugates changes the conversation around payload choice.
Technology
Myris ADCs utilize the ATRP ‘growing from’ technology to build polymer bottlebrushes on which payloads are attached.
The polymers convey solubility and ultra-high DAR.
Ultra-High DAR opens the payload landscape for ADCs enabling targeted therapy payloads for many oncogenic pathways.
Pipeline
